Pfizer CEO’s Stock Sale On Day Of COVID-19 Vaccine Announcement Raises Questions

NPR: Pfizer CEO Sold Millions In Stock After Coronavirus Vaccine News, Raising Questions
“The chairman and CEO of Pfizer, Albert Bourla, sold $5.6 million worth of stock in the pharmaceutical company on Monday. The sale took place on the same day Pfizer announced that its experimental coronavirus vaccine candidate was found to be more than 90% effective. The company’s stock soared on the news. Bourla sold the stock as part of a stock-trading plan that aims to shield corporate executives from allegations of illegal insider trading. … The timing of the implementation of Bourla’s plan, however, has raised questions about what the Pfizer CEO knew and when, and whether that may invite further scrutiny from federal regulators…” (Dreisbach, 11/11).

Additional coverage of Bourla’s stock sales is available from Axios, CNN Business, Financial Times, The Hill, Reuters, and Wall Street Journal.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.